中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-22
Tsoi Hoi Shan Attended Novo Nordisk Roundtable to Discuss the Global Impact of Chinese Innovation
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
All News
Select Year
2026
2025
2024
TUL Draws Attention at the 29th Macao International Trade and Investment Fair (MIF)
2024-10-23
TUL Showcases at CPHI Milan 2024, Italy
2024-10-17
TUL’s Class I Innovative Drug TUL12101 Eye Drops Completes First Patient Enrollment in China Phase IIa Clinical Study
2024-10-17
TUL’s Insulin Degludec Marketing Application Accepted by the National Medical Products Administration
2024-10-17
TUL’s Amoxicillin Granules (0.125 g) Pass Generic Drug Consistency Evaluation in Quality and Efficacy
2024-10-17
The United Laboratories (Inner Mongolia) Co., Ltd. Completes Pre-Approval Tazobactam and Ampicillin, and GMP Compliance Inspection for Newly Added Production Facility
2024-10-08
TUL Ranks 23rd in the “2023 Top 100 Chinese Pharmaceutical Industry Enterprises”
2024-09-20
TUL Receives “ESG Excellence in Comprehensive Governance” Award
2024-09-13
Zhuhai United Laboratories Co., Ltd. Passes German GMP Inspection
2024-09-05
Prev
1
...
12
13
14
15
16
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
